Research & Development
Cleveland BioLabs is leveraging deep mechanistic understanding of the cell death process to develop a robust pipeline of drugs for multiple medical and defense applications.
CBLI’s pipeline includes products from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation, chemotherapy and ischemias (pathologies developed as a result of blocking blood flow to a part of the body). Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer agents.
Between these two families, CBLI has four active compounds in development for five primary applications, two of which are in clinical trials.
|
